The current management team, who have been in place for approximately 1-1.5 year now, have proven themselves to be vastly superior to the previous team.
Atkins has refocused the company, built upon its impressive biotech assets, refined the Colostat kit, and is well on the way implementing a well trodden path to market.
The former team made many mistakes through lack of experience, they aimed too high too soon. The CEO during this period (Gilbert) was essentially promoted up from marketing. He replaced CSIRO scientist (Lockett) who had not headed up a company before.
RHY Price at posting:
6.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)